Your browser doesn't support javascript.
loading
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.
Suthar, Mehul S; Zimmerman, Matthew G; Kauffman, Robert C; Mantus, Grace; Linderman, Susanne L; Hudson, William H; Vanderheiden, Abigail; Nyhoff, Lindsay; Davis, Carl W; Adekunle, Oluwaseyi; Affer, Maurizio; Sherman, Melanie; Reynolds, Stacian; Verkerke, Hans P; Alter, David N; Guarner, Jeannette; Bryksin, Janetta; Horwath, Michael C; Arthur, Connie M; Saakadze, Natia; Smith, Geoffrey H; Edupuganti, Srilatha; Scherer, Erin M; Hellmeister, Kieffer; Cheng, Andrew; Morales, Juliet A; Neish, Andrew S; Stowell, Sean R; Frank, Filipp; Ortlund, Eric; Anderson, Evan J; Menachery, Vineet D; Rouphael, Nadine; Mehta, Aneesh K; Stephens, David S; Ahmed, Rafi; Roback, John D; Wrammert, Jens.
Affiliation
  • Suthar MS; Center for Childhood Infections and Vaccines; Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA 30322, USA.
  • Zimmerman MG; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Kauffman RC; Yerkes National Primate Research Center, Atlanta, GA 30329, USA.
  • Mantus G; Center for Childhood Infections and Vaccines; Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA 30322, USA.
  • Linderman SL; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Hudson WH; Yerkes National Primate Research Center, Atlanta, GA 30329, USA.
  • Vanderheiden A; Center for Childhood Infections and Vaccines; Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA 30322, USA.
  • Nyhoff L; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Davis CW; Center for Childhood Infections and Vaccines; Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA 30322, USA.
  • Adekunle O; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Affer M; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Sherman M; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Reynolds S; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Verkerke HP; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Alter DN; Center for Childhood Infections and Vaccines; Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA 30322, USA.
  • Guarner J; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Bryksin J; Yerkes National Primate Research Center, Atlanta, GA 30329, USA.
  • Horwath MC; Center for Childhood Infections and Vaccines; Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA 30322, USA.
  • Arthur CM; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Saakadze N; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Smith GH; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Edupuganti S; Center for Childhood Infections and Vaccines; Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA 30322, USA.
  • Scherer EM; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Hellmeister K; Center for Childhood Infections and Vaccines; Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA 30322, USA.
  • Cheng A; Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Morales JA; Emory Medical Laboratories, Emory Healthcare, Atlanta, GA 30322, USA.
  • Neish AS; Emory Medical Laboratories, Emory Healthcare, Atlanta, GA 30322, USA.
  • Stowell SR; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Frank F; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Ortlund E; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Anderson EJ; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Menachery VD; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Rouphael N; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Mehta AK; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Stephens DS; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Ahmed R; Hope Clinic of the Emory Vaccine Center, Emory University School of Medicine Decatur, Atlanta, GA, USA.
  • Roback JD; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Wrammert J; Hope Clinic of the Emory Vaccine Center, Emory University School of Medicine Decatur, Atlanta, GA, USA.
Cell Rep Med ; 1(3): 100040, 2020 06 23.
Article in En | MEDLINE | ID: mdl-32835303
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there is a pressing need to understand the development, specificity, and neutralizing potency of humoral immune responses during acute infection. We report a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. RBD-specific IgG responses are detectable in all patients 6 days after PCR confirmation. Isotype switching to IgG occurs rapidly, primarily to IgG1 and IgG3. Using a clinical SARS-CoV-2 isolate, neutralizing antibody titers are detectable in all patients by 6 days after PCR confirmation and correlate with RBD-specific binding IgG titers. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies Language: En Journal: Cell Rep Med Year: 2020 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies Language: En Journal: Cell Rep Med Year: 2020 Document type: Article Affiliation country: Country of publication: